Truvian Sciences, a San Diego, CA-based healthcare company at the intersection of diagnostics and consumer technology, closed a $27.1m Series B financing round.
The round, which brought total funds raised to date to $46.3m, was led by GreatPoint Ventures with participation from DNS Capital and Tao Capital Partners and existing investor Domain Associates.
The company intends to use the funds to expand operations and its development efforts.
Led by Jeff Hawkins, President and CEO, Truvian develops an automated benchtop system developed to produce lab-accurate results for a full-suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, the company’s system delivers an alternative to off-site labs, providing insights to inform healthcare decisions in 20 minutes.
The platform’s dry reagent technology allows consumables to be stored at room temperature, eliminating cold chain and refrigeration needs. Further, results will be delivered electronically to individuals through a digital platform. The company is working toward a CE Mark in the European Economic Area and a submission to the FDA for a 510(k) clearance along with a Clinical Laboratory Improvement Amendments (CLIA) waiver application that will allow for its system to be used in a retail setting or doctor’s office.
The company also added Katherine Atkinson as Chief Commercial Officer and industry veteran Paul Meister to its Board of Directors.
Dena Marrinucci, PhD, a life science entrepreneur who also co-founded Epic Sciences, is Truvian’s Co-founder and Senior Vice President of Corporate Development and Business Operations.
Truvian’s Board of Directors is chaired by Truvian Co-founder Kim Kamdar, Ph.D., a Partner with Domain Associates.